U.S. legislative proposals requesting the National Academies study feasibility and benefits of delinking pharmaceutical innovation from drug prices
KEI Briefing Note 2026:3
May 4, 2026
Zazie Huml
Several members of Congress have asked the U.S. National Academies to study the feasibility and likely impact of proposals to de-link the incentives for investing in biomedical R&D from the grant of temporary monopolies. Beginning in the 112th Congress, there have been five similar versions of the terms of reference for the study, included in 10 legislative proposals.